Viridian Therapeutics shares are trading higher after Needham raised its price target on the stock from $30 to $38.
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics shares are trading higher following an increase in the company's price target from $30 to $38.
September 11, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics has increased its price target from $30 to $38, leading to a rise in its stock price.
The increase in the price target suggests positive expectations for Viridian Therapeutics, which is likely to attract more investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100